All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
On 20 August 2018, the US Food and Drug Administration (FDA) granted Orphan Drug Designation to ASLAN003, a potent inhibitor of human dihydroorotate dehydrogenase (DHODH), for the treatment of patients with acute myeloid leukemia (AML).1
DHODH is an essential enzyme of de novo pyrimidine biosynthesis of DNA and RNA. David Skyes et al. have shown in a study that the inhibition of DHODH enables myeloid differentiation in human and mouse AML models.2 ASLAN003 is an orally active, potent inhibitor of DHODH, which have been shown to have the ability to differentiate AML blast cells into granulocytes in a variety of AML cell lines that do not respond to ATRA.
A phase IIa dose optimization study (NCT03451084), assessing the safety and efficacy of ASLAN003 as monotherapy in patients with AML is currently ongoing. The primary objective of the study is overall complete remission. The secondary objectives are the incidence of complete remission, relapse-free survival, clinical benefit rate and tumor percentage change.
References